Valuation
- Market cap
- 39,281,000
- Revenue TTM
- $29,620,000
- Net income TTM
- $-47,580,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -160.63%
- Debt to equity
- 0.00
Trading
- Volume
- 34,200
- Avg volume
- 36,202
- Day's range
- $9.23 – $9.75
- Shares out
- 4,045,000
- Stochastic %K
- 97%
- Beta
- 0.77
- Analysts
- Moderate Buy
- Price target
- $43.00
Company profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as we...
Show more
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 415 978 1200
- Website
- https://www.fibrogen.com
- Address
- 350 Bay Street, Suite 10 #6009, San Francisco, United States
Latest news
No headlines yet.
